NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

NEW YORK, July 21, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & As

BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi

Personalis, Inc. (PSNL) M&A Call Transcript

Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holdin

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

Lake Street analyst Thomas Flaten downgrades Personalis (NASDAQ:PSNL) from Buy to Hold and announ

BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price targ

Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD

Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to

Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Pub

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholde

MILWAUKEE, July 20, 2026 /PRNewswire/ -- Ademi LLP is investigating Personalis (NASDAQ: PSNL) for po

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion,

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer

Tempus ​AI said ‌on Monday ​it ​would acquire ⁠Personalis ​for about $1.5 ​billion to bringing ​its

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal dat

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption o

Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price ta

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-

This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Re

Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and ra

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announce

Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clini

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announce

Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients unde

Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and lo

BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price targ

Personalis (NASDAQ:PSNL) affirms FY2026 sales outlook from $78.000 million-$80.000 million to $78.00

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.29) per share which missed the analyst con

Podium presentation on NeXT Personal monitoring neoadjuvant therapy in colorectal cancer;Real-world

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced toda

The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer acro

Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and lo

Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price ta

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.26) per share which beat the analyst conse

BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price targ

Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung can

This coverage determination is grounded in clinical evidence generated through the company's col